Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma

Journal of Nuclear Medicine

Volumn 39, Issue 9, 1998, Pages 1586-1590

  Gasparini, Massimo ^a   Bombardieri, Emilio ^b   Castellani, Massimo ^b   Tondini, Carlo ^b   Maffioli, Lorenzo ^b   Devizzi, Liliana ^b   Gerundini, Paolo ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE

Author keywords

Chemotherapy; Gallium scintigraphy; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GALLIUM CITRATE GA 67; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SCINTIGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CITRATES; FEMALE; GALLIUM; GALLIUM RADIOISOTOPES; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 0031677804     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Mad 1993;329:987-994.
2. DeVita VT, Hubbard SM, Young RC, et al. The role of chemotherapy in diffuse aggressive lymphomas. Semin Hematol 1988;25:2-10.
3. Jochelson M, Mauch P, Bilikian J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985;3:637-640.
4. Israel O, Front D, Ebelbaum R, et al. Residual mass and negative gallium scintigraphy in treated lymphoma. J Nucl Med 1990;31:365-368.
5. Wylie BR, Southee AE, Joshua DE. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 1989;42:344-347.
6. Lewis E, Bernardino ME, Salvator PG, Cabanillas FF, Barnes PA, Thomas JL. Post-therapy CT-detected mass in lymphoma patients: is it viable tissue? J Comput Assist Tomogr 1982;6:792-795.
7. Chen JL, Osborne BM, Butler JJ. Residual fibrous masses in treated Hodgkin's disease. Cancer 1987;60:407-413.
8. Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988;6:940-946.
9. Front D, Ben-Haim S, Israel O, et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology 1992;182:359-363.
10. Karimjee S, Brada M, Husband J, McCready VR. A comparison of gallium-67 single photon emission computed tomography and computed tomography in mediastinal Hodgkin's disease. Eur J Cancer 1992;28A:1856-1857.
11. Tesoro-Tess JD, Balzarini L, Ceglia E, et al. Magnetic resonance imaging in the initial staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Radiology 1991;12:81-90.
12. Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapses in residual masses after treatment of lymphoma. J Clin Oncol 1993;11:2273-2278.
13. Gasparini M, Balzarini L, Castellani MR, et al. Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993;72:577-582.
14. Nyman RS, Rehn SM, Glimelius BLG, et al. Residual mediastinal masses in Hodgkin's disease: prediction of size with MR imaging. Radiology 1989;170:435-440.
15. Frija J, Bris C, Yarner C, et al. MRI with gadolinium of post therapeutic residual masses in lymphoma [Abstract]. Eur J Radiol 1991;1(suppl):17.
16. Okada J, Yoshikawa K, Imazeky K, et al. The use of FDG PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991;32:686-691.
17. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensum H. Uptake of carbon-11-methionine and fluorodeosyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991;32:1211-1218.
18. Kubota R, Yamada S, Kubota K, Ishiwata K, Ido T. Microautoradiographic study of F-18-FDG: high accumulation in granulation tissues and phagocytes in mouse tumor in vivo [Abstract]. J Nucl Med 1992;33:840.
19. Wahl RL, Clavo A, Brown RS, Roessner J. 2-Fluoro-2-deoxy-D-glucose (FDG) uptake into human cancer cell lines is increased by hypoxia [Abstract]. J Nucl Med 1992;33:841.
20. 3]deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 1985;26:278-282.
21. Straus DJ. Modern approaches for Hodgkin's disease. Curr Opin Oncol 1993;5:785-790.
22. von Gunten CF, Gordon LI. Treatment of advanced, aggressive non-Hodgkin's lymphoma. Curr Opin Oncol 1993;5:791-796.
23. Peylan-Ramu N, Haddy TB, Jones E, et al. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 1989;7:1800-1806.
24. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988;6:931-933.
25. Stewart FM, Williamson BR, Innes DJ, et al. Residual tumor masses following treatment for advanced histiocytic lymphoma. Diagnostic and therapeutic implications. Cancer 1985;55:620-623.
26. Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large cell lymphoma: rapidly responding patients have more durable remissions. J Clin Oncol 1986;4:160-164.
27. Kaplan WD, Jochelson MS, Herman TS, et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990;8:1966-1970.
28. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-deoxy-d-glucose: correlation with CT. Radiology 1994;190:111-116.
29. Heokstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993;34:1706-1710.